PT1385577E - Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna - Google Patents

Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna

Info

Publication number
PT1385577E
PT1385577E PT02719751T PT02719751T PT1385577E PT 1385577 E PT1385577 E PT 1385577E PT 02719751 T PT02719751 T PT 02719751T PT 02719751 T PT02719751 T PT 02719751T PT 1385577 E PT1385577 E PT 1385577E
Authority
PT
Portugal
Prior art keywords
utilization
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
Prior art date
Application number
PT02719751T
Other languages
English (en)
Portuguese (pt)
Inventor
Buser Susanne
Anthony P D W Ford
Hoffmann Torsten
Lenz Barbara
Sleight Andrew John
Vankan Pierre
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1385577E publication Critical patent/PT1385577E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02719751T 2001-04-23 2002-02-02 Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna PT1385577E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
PT1385577E true PT1385577E (pt) 2006-08-31

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02719751T PT1385577E (pt) 2001-04-23 2002-02-02 Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
HRP20050664A2 (en) * 2003-01-31 2006-12-31 F. Hoffmann - La Roche Ag NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
ES2291891T3 (es) * 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
NZ595723A (en) 2009-03-17 2012-10-26 Daiichi Sankyo Co Ltd Amide derivative
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
EP2493299A4 (en) * 2009-10-29 2013-04-17 Merck Sharp & Dohme TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US11801244B2 (en) * 2018-02-02 2023-10-31 Eustralis Pharmaceuticals Limited Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
CA2298702A1 (en) * 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
KR20010022581A (ko) * 1997-08-06 2001-03-26 피터 지. 스트링거 타키키닌 수용체 길항제인 2-아실아미노프로판아민
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
DK1385577T3 (da) 2006-08-21
ZA200308110B (en) 2005-03-30
JP4146730B2 (ja) 2008-09-10
CN1503684A (zh) 2004-06-09
EP1385577A2 (en) 2004-02-04
DE60210760T2 (de) 2006-11-23
ES2261657T3 (es) 2006-11-16
ATE323531T1 (de) 2006-05-15
MXPA03009720A (es) 2004-01-29
CA2444395C (en) 2010-12-21
CN100398106C (zh) 2008-07-02
JP2004529931A (ja) 2004-09-30
WO2002085458A3 (en) 2003-10-30
US20030004157A1 (en) 2003-01-02
CA2444395A1 (en) 2002-10-31
KR100599134B1 (ko) 2006-07-12
BR0209151A (pt) 2004-07-13
DE60210760D1 (de) 2006-05-24
WO2002085458A2 (en) 2002-10-31
AR035935A1 (es) 2004-07-28
KR20040007503A (ko) 2004-01-24
AU2002250876B2 (en) 2005-03-03
EP1385577B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
DK1385577T3 (da) Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
GB2376049B (en) Controlling activation of devices
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
ATE400558T1 (de) Metabotropische glutamatrezeptor-antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
DE50111858D1 (de) Zerstäuberbrenner
IL158701A0 (en) Novel use of nk3 receptor antagonist
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
FI20001512L (fi) Salaamattoman käyttäjäliikenteen kontrollointi
NO20015779D0 (no) Bradykinin-reseptorantagonister
ATE374183T1 (de) Nk1-antagonisten
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
AU2002216079A1 (en) Bombesin receptor antagonists
GB0011817D0 (en) Antagonists of integrin receptors
ID30023A (id) Kombinasi senyawa aktif fungisida
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin
AU2002217095A1 (en) Bombesin receptor antagonists
IT1320031B1 (it) Disposizione di reti.
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii
NO20004142D0 (no) Ftalimidoarylpiperaziner som <alfa> 1A reseptorantagonister anvendelige ved behandling av benign prostatahyperplasi
GB2373456B (en) Dilution of chemicals
GB0112611D0 (en) Patterning of devices
MXPA03004249A (es) Nuevos usos de combinaciones selectivas antagonistas del receptor de dopamina d2 y agonistas del receptor de 5-ht1a.
DE10191779T1 (de) Aktivitätenmeldungserzeugung